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ABSTRAK 
Teknologi maklumat telah menjadi sebahagian daripada ilmu pengetahuan dalam 
bidang sains. Penelitian saintis bersama ahli akademik secara serius berfikir tentang 
perlunya teknologi maklumat dalam ilmu farmasi termasuk farmasi klinikal dan 
penjagaan farmaseutikal. Teknologi maklumat telah diterapkan secara tidak langsung 
dalam proses penemuan perubatan dan rawatan pesakit untuk jangka masa yang 
panjang. Farmasi informatik melibatkan kajian, rekabentuk, dan pelaksanaan maklumat 
dan sistem maklumat farmasi. Pembangunan pengkalan data secara berkomputer on 
preskripsi diatas talian dan data data maklmal telah meningkatkan kemampuan institusi 
institusi dan organisasi kesihatan untuk meneliti kesan advers (ADR) yang kerap 
berlaku. Kajian ini mempunyai empat tujuan utama; Objektif pertama adalah untuk 
membangunkan model secara matematik untuk mengira peratusan kemungkinan 
berlakunya ADR menggunakan maklumat yang berkaitan dengan pesakit. Objektif 
kedua adalah untuk menilai kewujudan maklumat penting dalam literatur perubatan 
yang sedia ada menggunakan model ramalan ADR. Objektif ketiga adalah untuk 
menguji fungsi model tersebut. Keempat objektifnya adalah untuk melakukan proses 
validasi bagi memastikan fungsinya untuk menjangkakan kesan ADR. Literatur 
perubatan yang berkaitan dengan keselamatan dan efikasi drug antihipertensi digunakan 
sebagai sumber maklumat. Maklumat ini merangkumi semua data yang berkaitan 
pesakit dan rawatannya. Data ini memainkan peranan penting dalam pembangunan 
model ADR ini. Pengiraan ini bergantung pada koleksi data yang berkaitan dengan 
pesakit yang akan mempengaruhi berlakunya kesan ADR ini. Untuk mengoptimalkan 
maklumat yang dikumpul daripada literatur yang diperolehi, pengkelasan berdasarkan 
 xv
faktor pesakit dilakukan untuk pengiraan yang tepat. Microsoft akses digunakan untuk 
model struktur dan pembangunan. Selepas kemasukan data, maklumat yang dikumpul 
akan dianalisis untuk sebarang maklumat yang hilang. Analisis ini dilakukan 
menggunakan Microsoft akses dan program SPSS. Pengujian model dilakukan dengan 
menghasilkan laporan tentang ADR untuk drug antihipertensi. Laporan ini selektif 
untuk drug drug dan faktor-faktor pesakit yang tertentu. Validasi model diperolehi 
dengan kajian perbandingan antara peratusan ADR untuk Amlodipine yang dihitung 
daripada model dan kadar sebenar berlakunya ADR daripada rekod perubatan pesakit di 
hospital. Paduan t-test untuk variabel independen digunakan untuk pengujian dengan 
95% confidence interval. Keputusan akhir kajian ini adalah pengembangan konsep baru 
untuk jangkaan ADR. Model ini akan menghitung kadar peratusan minimum dan 
maksimum berlakunya ADR dalam pesakit yang spesifik. Analisis data tentang 
maklumat yang hilang dalam literatur perubatan membawa masalah ini menjadi 
perhatian. Banyak maklumat yang hilang termasuk berkaitan dengan pesakit, rawatan 
dan ADR. Model ini juga diuji untuk kefungsian dengan menganalisis beberapa drug 
antihipertensi berlakunya ADR. Tidak ada perbezaan yang signifikan secara statistik 
(nilai p 0,46) antara peratusan ADR Amlodpine daripada pesakit dan yang dikira 
dengan menggunakan model ramalan ADR. Pemanfaatan teknologi maklumat 
menyediakan masa depan yang lebih cerah yang dalam penggunaan drug dan 
membantu dalam membuat keputusan dalam pemilihan drug yang sesuai. Kajian ini 
mengembangkan pendekatan baru untuk farmakoinfomatik klinikal untuk 
menjangkakan berlakunya ADR. 
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Abstract 
Information technology has become part of all kinds of sciences. Research scientists 
along with the academicians are seriously thinking about the need of information 
technology in pharmaceutical sciences including clinical pharmacy and pharmaceutical 
care. Information technology has been applied indirectly in the medication discovery 
process and patient care for a long period of time. Pharmacy Informatics involves the 
study, design, and implementation of information and information systems in 
Pharmacy. The development of computerized prescriptions and laboratory databases has 
greatly enhanced the ability of institutions and organizations to screen for known 
adverse drug reactions (ADR). This research has four main objectives; first objective is 
to develop a mathematical model to calculate the percentage of possible occurrence of 
ADRs using patients related information. Second objective is to evaluate the availability 
of essential information in medical literature using the ADR prediction model. Third 
objective is to test the model for its functionality. Fourth objective is to validate the 
model. Medical literature on antihypertensive medication safety and efficacy is used as 
a source of information. This information includes all patient related and medication 
related data. These data play an important role in the development of ADRs. The 
calculation depends on the collection of patient related factors which affect the 
development of the ADRs. For the optimal utilization of information collected from 
literature, classification of patient factors is done for proper calculation. Microsoft 
access is used for model structure and development. After data entry, information 
collected from literature were analyzed for missing information. The analysis was done 
using Microsoft access and SPSS programmes. Testing the model is accomplished by 
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generating reports on ADRs for antihypertensive medications. These reports are 
selective for certain medications and certain patients factors. Model validation was 
achieved by a comparative study between the percentage of ADRs for Amlodipine 
calculated from the model and the actual occurrence of ADRs from hospital patients 
medical records. Paired t-test for independent variables is used for testing with 
confidence interval of 95%. The end product of this research is the development of a 
new concept for the prediction of ADRs. This model calculates the minimum and the 
maximum percentage of ADR occurrence in specific patient. Data analysis regarding 
missing information in medical literature brought this problem into attention. Many 
kinds of information are missing including patient, medication and ADR related 
information. The model is also tested for its functionality by analyzing some of the 
antihypertensive medications for their ADR occurrence. There is no statistically 
significant difference (p value 0.46) between ADR percentage of Amlodpine from 
actual patients and the calculated ones using ADR prediction model. The utilization of 
information technology provides a promising future for the safe use of medications and 
helps in medical decision making and proper medication selection. This study develops 
a new clinical pharmacoinformatics approach for the prediction of ADRs.  
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Chapter 1 
Introduction 
1.1. Background 
1.1.1. Adverse Drug Reactions (ADRs) 
Safety issues arise whenever medical choices have to be made (Bauer, 2008). ADRs can 
occur in all settings where healthcare is provided. Most of the current evidence comes 
from hospitals because the risks associated with hospital treatment are higher 
(Yurdaguel, et al., 2008). Many such events occur in other healthcare settings such as 
consulting rooms, nursing homes, pharmacies, community clinics and patients’ homes 
(Handler, et al., 2008).  
 
While the drug discovery process has been revolutionized by new techniques, drug 
safety assessment lags well behind and is still reliant on many of the same technologies 
that have been used for several decades (Powley, et al., 2009). Current conceptual 
thinking on the safety of patients places the prime responsibility for ADRs on 
deficiencies in system design, organization and operation - rather than on individual 
practitioners or products. Berwick and Leape, (1999) recommended that checks and 
quality assurance should be built into the use system, rather than assuming that all will 
be well. 
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By the time a drug is marketed, only about 1500 patients may have been exposed to the 
drug. Thus, only those ADRs occurring at a frequency of greater than 1 in 500 will have 
been identified at the time of licensing (Andrade, et al., 2007).  Pirmohamed, et al. 
(1998) suggested that the assessment of ADRS therefore is likely to represent an 
important aspect of drug therapy. Silverman, et al. (2003) showed that the overall rate 
of ADRs is estimated to be 6.5 per 100 admissions; 28% of these reactions are 
preventable. 
 
Once put onto the market, a drug leaves the secure and protected scientific environment 
of clinical trials and is legally set free for consumption by the general population 
(Russell, et al., 1992). At this point, most drugs will only have been tested for short-
term safety and efficacy on a limited number of carefully selected individuals. 
 
In order to prevent or reduce harm to patients and thus improve their health, 
mechanisms for evaluating and monitoring the safety of drugs in clinical use are vital. 
In practice this means having in place a well-organized pharmacovigilance system. 
Pharmacovigilance - an umbrella term used to describe the processes for monitoring and 
evaluating ADRs is a key component of effective drug regulation systems, clinical 
practice and public health programmes. 
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The World Health Organization [WHO], (2003) defines pharmacovigilance as the 
science and activity relating to the detection, assessment, understanding and prevention 
of ADRs or any other drug related problem. The most important task of the WHO 
International Drug Monitoring is to identify ADR signals of drug safety problems as 
early as possible. Events such as the thalidomide tragedy highlight the extreme 
importance of effective drug monitoring systems for all drugs (Neubert, et al., 1995). 
The principal aims of pharmacovigilance programmes are:  
• To improve patient care and safety in relation to the use of drugs, and all medical and 
paramedical interventions; 
• To improve patient health and safety in relation to the use of drugs; 
• To contribute to the assessment of benefit, harm, effectiveness and risk of drugs, 
encouraging their safe, rational and more effective (including cost-effective) use; 
• To promote understanding, education and clinical training in pharmacovigilance and 
its effective communication to health professionals and the public. 
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1.1.2. Pharmacoinformatics 
Both in science and in healthcare, methods of thinking and actions are dominated by 
man-made rules or laws that have been discovered and theories that have been 
developed in the course of scientific research. Computers facilitate the process of 
structuring and ordering the world, both in science and in society at large. Thus, in this 
research and in virtually all areas of modern society computers have become 
indispensable. Pharmacoinformatics is an important branch of information technology 
in which pharmacology and information systems are merged. 
 
Pharmacoinformatics is one of the latest terms added to the specialized informatics 
sciences which more or less flourished with the information technology revolution in 
the 1990’s (Rochon, et al., 2006). Information technology which uses the computer for 
data processing and decision making has influenced all kind of sciences. Many of the 
industrialist and research scientists and academicians are seriously thinking about the 
need of information technology in pharmaceutical sciences including clinical pharmacy 
and pharmaceutical care (Spiro, et al., 2010). Information technology has been applied 
indirectly in the drug discovery process and patient care for a long period of time 
(James, et al., 2009). 
 
Pharmacists should be involved in the original conceptual design of some systems that 
advance information technology to a higher level in Pharmacy Practice. This 
involvement will enable pharmacists to utilize computer technology to the maximum 
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level for the purpose of patient care and safety. Pharmaconformatics involves the study, 
design and implementation of information and information systems in pharmacy. 
 
In the academic setting, Pharmacoinformatics can be better organized such that 
information for students or members provides a better quality of learning. Educational 
materials that are indexed, cross-referenced and reviewed properly are easily converted 
to a database that can be made available via the Web, in a slide-show format, textbooks, 
or pamphlets. Teaching pharmacy students from the very beginning to adopt technology 
on a proactive basis can make them more prepared to accept this technology in their 
future work places like hospitals, community pharmacies and universities. 
 
By improving the computer information systems for the pharmacist, the pharmacy 
informatics specialist assists other healthcare providers through different ways. First, 
the pharmacist makes the information more readily available in many shapes and forms 
which can be utilized by other healthcare professionals. By arranging these systems 
properly, a comprehensive resource for drug information can be created. Second, 
pharmacists who spend less time dealing with old standard information systems are now 
available for their patients, practicing patient counseling, drug monitoring and follow-
up. This also gives them ample time to provide training for other healthcare 
professionals in the institution. 
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1.2. Aims 
The aim of this research is to develop a model for the prediction and calculation of the 
possible occurrence of ADRs in a specific population. This can be done using certain 
factors mentioned in medical literature which affect the development of that ADR. The 
aim of the model is to minimize ADRs and help in choosing the best drug of choice. 
 
This research will generate a concept for creating and utilizing the clinical decision 
support systems which are the active knowledge systems using two or more items of 
patient data to generate case-specific - advice. 
 
Clinical characteristics that might be used as predictors of the clinical outcome may 
include quite diverse features, depending on the particular clinical problem. 
 
The development of this model allows it to be used with any drug. However, for 
simplicity and to further clarify the concept of this model, antihypertensive drugs were 
selected. 
 
1.3. Scope of research 
Due to the deficiency of the currently available pharmacoinformatic systems, the 
incidence of ADRs are not satisfactorily prevented (Demiris, et al., 2008). This creates 
an urgent need for a new research approach in this field. It is worth undertaking 
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research on the use of information technology in ADR predictions. Accordingly, this 
research will provide a model which enables healthcare professionals to explore and 
identify the incidence of ADRs for specific drugs. The resulting model should lead to 
improving pharmacotherapeutic outcomes. This research, therefore, has been structured 
around four key questions. Firstly, what are the external factors that influence the 
occurrence of ADRs? To answer this question, certain environmental factors which 
surround the patient during the treatment period must be studied. Secondly, what are the 
internal factors (patient related factors) that affect the body making it more vulnerable 
to ADRs? This question demands the identification of biological and pharmacokinetic 
differences between patients. Thirdly, what are the expectations and purposes of 
developing an ADR prediction model? This question requires the assessment of 
available pharmacoinformatic technology and the actual impact of such technology on 
patient pharmacotherapeutic outcomes. 
 
Finally, the last question, what are the challenges of implementing such technology in 
the medical field? This final question will be covered in detail in the final discussion. 
 
1.4. Research objectives 
In order to meet the aims of developing an ADR prediction model, the following 
objectives need to be fulfilled: 
1. Develop a mathematical approach for the prediction of ADRs using a selected 
number of antihypertensive drugs as a basis for the model.  
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2. Calculate the exact effect of each causative factor on the development of ADRs 
for a specific drug. 
3. Evaluate the validity of the data extracted from literature about the prevalence of 
ADRs and the possibility of implementing this data on certain populations.  
4. Evaluate the effect of poly-pharmacy on the occurrence of ADRs. 
5. To evaluate the availability of detailed information about the number and 
percentage of patients who developed ADRs in medical literature.  
 
1.5. Type of data collection 
The primary source of data will be from medical literature. This data will be about the 
percentage of ADR occurrence in specific patients, considering their specific causative 
factors and evaluating the effect of these factors on that percentage. The causative 
factors and their effect on ADR occurrence will be evaluated through medical literature. 
Also the actual occurrence of ADRs will be evaluated considering these causative 
factors. These two results will be compared. 
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Chapter 2 
Literature review 
2.1. Background  
This chapter will discuss the following sections; definition and seriousness of ADRs, 
the importance of information systems in detecting, reporting and preventing ADRs, 
factors affecting the occurrence of ADRs and the need for more advanced 
pharmacoinformatic models for ADR prediction. 
 
2.2. Literature review on ADRs 
2.2.1. Definition of ADRs 
ADR is defined as a response to a drug which is noxious and unintended, and which 
occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of 
disease, or for the modification of physiological function (WHO, 1972). It is also 
defined as an undesirable effect, reasonably associated with the use of the drug that may 
occur as a part of the pharmacological action of a drug or may be unpredictable in its 
occurrence (Edwards, 2000). Medical literature mentioned many other definitions 
related to adverse events in addition to ADRs, these definitions are;  
1. Unexpected Adverse Reaction is an adverse reaction in which the nature or 
severity of it is not consistent with domestic labeling or market authorization, or 
expected from characteristics of the drug (Brennan, et al., 2004). 
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2. Adverse Event / Adverse Experience are any untoward medical occurrence that 
may present during treatment with a pharmaceutical product but which does not 
necessarily have a causal relationship with this treatment. This is a more recent 
term which some use interchangeably with adverse reaction, but, as indicated, it 
is better reserved for clinical phenomena occurring during drug treatment where 
the possibility of a causal connection has not been considered (Meyboom, et al., 
1997). 
 
3. Side Effect is any unintended effect of a pharmaceutical product occurring at 
doses normally used in man which is related to the pharmacological properties 
of the drug. This is an old term and is broad enough to include both positive and 
negative effects of a drug apart from its main properties or indications. Some use 
the term as synonymous with adverse reaction, but the proposed definition will 
improve clarity of use of this term (Evans, et al., 2003). 
 
4. The signal is reported information on a possible causal relationship between an 
adverse event and a drug, the relationship being unknown or incompletely 
documented previously. Usually more than a single report is required to generate 
a signal, depending upon the seriousness of the event and the quality of the 
information (Nebeker, 2004). Signal describes the first alert of a problem with a 
drug. By its nature a signal cannot be regarded as definitive but indicates the 
need for further enquiry or action. On the other hand it is prudent to avoid a 
multiplicity of signals based on single case reports since follow up of all such 
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would be impractical and time consuming. The definition allows for some 
flexibility in approach to a signal based on the characteristics of individual 
problems. Some would like a signal to include new information on positive drug 
effects, but this is outside the scope of a drug safety programme (Veenstra, 
2001). 
 
5. Serious adverse event or reaction is any untoward medical occurrence that at any 
dose:  
• Results in death. 
• Requires inpatient hospitalization or prolongation of existing hospitalization. 
• Results in persistent or significant disability/incapacity. 
• Is life-threatening. 
 
To ensure no confusion or misunderstanding of the difference between the terms serious 
and severe, the following note of clarification is provided: The term severe is not 
synonymous with serious. In the English language, severe is used to describe the 
intensity (severity) of a specific event (as in mild, moderate or severe); the event itself, 
however, may be of relatively minor medical significance (such as severe headache). 
Seriousness (not severity) which is based on patient/event outcome or action criteria 
serves as guide for defining regulatory reporting obligations (Wooten, 2009). 
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1. Certain is a clinical event, including laboratory test abnormality, occurring in a 
plausible time relationship to drug administration, and which cannot be 
explained by concurrent disease or other drugs or chemicals. The response to 
withdrawal of the drug (dechallenge) should be clinically plausible. The event 
must be definitive pharmacologically or phenomenologically, using a 
satisfactory rechallenge procedure if necessary (Molokhia, et al., 2009). 
 
2. Probable/ likely is a clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, unlikely to be attributed 
to concurrent disease or other drugs or chemicals, and which follows a clinically 
reasonable response on withdrawal (dechallenge). Rechallenge information is 
not required to fulfill this definition (Puijenbroek, et al., 2001). 
 
3. Possible is a clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, but which could also be 
explained by concurrent disease or other drugs or chemicals. Information on 
drug withdrawal may be lacking or unclear (Puijenbroek, et al., 2001). 
 
4. Unlikely is a clinical event, including laboratory test abnormality, with a 
temporal relationship to drug administration which makes a causal relationship 
improbable, and in which other drugs, chemicals or underlying disease provide 
plausible explanations (Castel, et al., 2003). 
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5. Conditional/ unclassified is a clinical event, including laboratory test 
abnormality, reported as an adverse reaction, about which more data is essential 
for a proper assessment or the additional data are under examination (Naranjo, et 
al., 1981). 
 
6. Unassessible / unclassifiable is a report suggesting an adverse reaction which 
cannot be judged because information is insufficient or contradictory, and which 
cannot be supplemented or verified (Nebeker, et al., 2004). 
 
2.2.2. Classification of ADRs 
Gharaibeh, et al. (1998) mentioned the following classifications for ADRs severity:  
• Mild; No antidote or treatment is required; hospitalization is not prolonged.  
• Moderate; A change in treatment (eg, modified dosage, addition of a drug), but 
not necessarily discontinuation of the drug, is required; hospitalization may be 
prolonged, or specific treatment may be required. 
• Severe; An ADR is potentially life threatening and requires discontinuation of 
the drug and specific treatment of the ADR. This definition is debatable since 
severity and seriousness is completely different issues. 
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2.2.3. Types of ADRs 
ADRs are divided into many types depending on the nature, location, causality, and 
seriousness of the reaction. The types are: 
2.2.3.1. Type A Adverse Effects: Drug Actions  
Type A effects are adverse effects in the true sense of the word. They are 
pharmacological actions as much as therapeutic effects are; the essential difference 
being that they are unintended. Examples are constipation during the use of morphine 
for analgesia, or sedation caused by a hypnotic. Undoubtedly, type A effects are by far 
the most prevalent (Trick, 1996). As a rule there is a dose-response relationship: type A 
effects are more frequent and more severe when higher doses are taken. There is often 
also a suggestive time relationship between exposure and effect, in accordance with the 
pharmacokinetic or pharmacodynamic properties of the drug. Because of their 
pharmacological nature, type A effects are comparatively easy to study. 
 
Clinical trials give information on the efficacy and tolerability; the latter is largely 
determined by type A adverse effects. In addition, type A effects can often be 
reproduced and clarified in a variety of experimental tests (e.g. animal experiments or in 
vitro studies) (Aronson & Ferner, 2003). 
 
Nevertheless, there are many possible reasons why a predominantly pharmacological 
effect may be less easy to demonstrate and may not be detected in a clinical trial. The 
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delayed discovery of coughs induced by ACE inhibitors years after their introduction, is 
an example (Pylypchuk, 1998). A high background frequency or unspecificity of the 
event may blur the relation with the drug; the mechanism may be unrelated to the 
therapeutic action of the drug; the effect may only develop after prolonged 
administration of the drug. In the example of coughs and ACE inhibitors a clear dose 
response-relationship could not be demonstrated, suggesting the existence of a sensitive 
subpopulation. A variety of pharmacological (type A) effects occur mainly in special 
situations or patients with increased susceptibility, for example, demographic 
determinants, pre-existent disturbances of drug handling, special physiological states, or 
concomitant use of other medicines or drugs (Aronson & Ferner 2003). 
 
There are many drugs that are generally well tolerated, but exert selective toxic effects 
on one particular organ, tissue or structure, for instance because of accumulation or the 
production of toxic metabolic intermediates in the particular tissue. Examples are 
aminoglycoside and ototoxicity or chloroquine-induced retinopathy (‘bull’s eye’) 
(Meyboom, et al., 2000). 
 
There are many examples of type A effects that take months or even years of drug use 
to develop (e.g. tardive dyskinesia induced by antipsychotics) (Schooler, et al.,1982). 
Their detection may be difficult because of the absence of a suggestive time 
relationship. 
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There are many different physiological or pathological states that predispose to the 
development of basically pharmacological effects. Pregnancy, lactation, childhood, 
elderly, decreased renal clearance or haemodialysis, all have characteristic features 
which may allow medicines to exhibit effects that would otherwise be rare or could not 
occur (Forfar & Nelson, 1973) . The notorious teratogenicity of thalidomide is a clear 
example. Because trial patients are selected, clinical trials are unlikely to yield 
information regarding such special populations (Neubert, et al., 1995). Other methods 
of detection, for example those used for type B adverse effects, may be needed 
(Aspinall, et al., 2002). 
 
Since many drugs may interact in many different ways, drug-drug, drug-food or 
medicine-drug (e.g. alcohol) interactions play an important role in pharmacovigilance 
(David, 2000). Because of their pharmacological mechanism, interactions can often be 
classified as type A effects. Sometimes drugs react physicochemically when exposed 
outside the body, for example, when injected into an intravenous line (Zwart-van 
Rijkom, et al., 2009). 
 
2.2.3.2. Type B Adverse Effects: Patient Reactions 
The second major category, the type B adverse effects, refers to the phenomenon that a 
drug is well tolerated by the (vast) majority of users, but occasionally elicits an allergic 
reaction (Rawlins, 1995). Often and characteristically, type B effects are acute, 
unexpected and severe (Trick, 1996). 
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Type B adverse effects are a major reason for withdrawal of drug from the market 
(Aronson1 & Ferner, 2005). Characteristically, there is little or no dose relationship: the 
reaction is not more frequent or more severe in patients using higher doses. Therefore, 
type B effects are depicted to be opposite type A effects. Type B adverse effects are 
either immunological or nonimmunological forms of hypersensitivity and occur in 
patients with an, often unknown or unrecognised, predisposing condition. 
Immunoallergic reactions may have complex pathology and take many forms, ranging 
from nonspecific rashes to specific reactions such as cholestatic hepatitis, 
agranulocytosis or autoimmune syndromes. Several drugs are known directly that is, 
without the involvement of an antigen-antibody reaction to release mediators of 
inflammation (notably histamine) and elicit pseudoallergic reactions, for instance 
morphine-induced urticaria or aspirin (acetylsalicylic acid)-mediated bronchospasm 
(Roederer, et al., 1991). 
 
The notion of ‘intolerance’ usually refers to patients with an excessive response to a 
normal dose of a drug, for example, because of a slow metabolism (Troisi, et al., 1985).  
The response is qualitatively normal but quantitatively excessive.  
 
In the case of idiosyncrasy (a word indicating that the reaction is determined by the 
constitution of the patient), the response is also qualitatively different (Westphal, et al., 
1998). Among the many examples are haemolytic reactions in patients with glucose-6-
18 
 
phosphate dehydrogenase (G6PD) deficiency and, possibly, phenylbutazonerelated 
aplastic anaemia (Ulrich, 2006). Type B adverse effects are notoriously difficult to 
study experimentally and often the mechanism is not known or not fully clarified 
(Dominguez, 2000). There are several examples that a drug was withdrawn because of 
an idiosyncratic reaction, whereas the underlying mechanisms was never elucidated (a 
striking example was the practolol-associated sclerosing peritonitis) (Brown, et al., 
1974). 
 
That type B adverse effects, in spite of so much difficulty, are often readily detected, is 
explained by the situation that these effects often occur in a suggestive time relationship 
with drug exposure, are characteristic and have a low background frequency. In this 
light it is understandable why spontaneous reporting, the major system used by national 
pharmacovigilance centres, has been found to be especially effective in detecting type B 
adverse effects (Meyboom, et al., 1992).  
 
2.2.3.3. Type C Adverse Effects 
Since the controversy regarding increased cardiovascular mortality in patients with 
diabetes mellitus using oral hypoglycaemic drugs emerging from the prestigious 
University Diabetes Group Diabetes Program report in the early seventies, numerous 
connections have been assumed to exist between drug exposure and disease frequency 
(Garratt, et al., 1999). Another example is the increased overall occurrence of malignant 
diseases observed in clofibrate-users in a large multinational study of the prevention of 
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ischaemic heart disease (Rosenhamer & Carlson, 1980). Such type C adverse effects 
can be defined as the increased occurrence of a given disease in patients using a 
particular drug, as compared with the (relatively high) background frequency in 
unexposed patients. Compared with type B adverse effects, type C effects have a higher 
background frequency and a less obvious time relationship (Bankowski, et al., 1999). 
Type C adverse effects, like type B adverse effects, are often difficult to study in 
experimental models and the mechanism often is unknown (Bankowski, et al., 1999). 
 
2.2.3.4. Indirect Adverse Effects 
Apart from therapeutic administration, drug can, throughout the process of production, 
distribution and destruction, give rise to health hazards in a variety of ways. A 
production error during drug manufacturing could lead to contamination of the 
environment with a toxic intermediary or waste product. Widely used drugs, that are 
excreted unchanged or as an active metabolite may be traceable in the surface water. 
Meyboom, et al. (2000) found that antibacterial use in, for instance in bio-industry, may 
lead to bacterial resistance development. 
 
2.2.4. Magnitude of ADRs  
A serious ADR is any untoward medical occurrence that at any dose; results in death, 
requires inpatient hospitalization or prolongation of existing hospitalization, results in 
persistent or significant disability/incapacity, or is life-threatening (Aronson, et al., 
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2003). Serious ADRs are usually preventable, and reducing severe ADRs can be 
accomplished by strategies targeting the prescribing habits and the monitoring plans and 
follow-up. 
 
ADRs are one of the leading causes of morbidity and mortality in healthcare. The 
Institute of Medicine, in the United States (US) (2000) reported that between 44,000 to 
98,000 deaths occur annually from medical errors. Of this total, an estimated 7,000 
deaths occur due to ADRs. Analyzing 39 studies of the American pharmaceutical 
system over four decades found that in 1994, 106,000 people died as a result of ADRs.  
More than 2 million suffered serious side effects (Pomeranz, 1998). These figures 
showed that there was a trend of increasing death and injury from ADRs during the 
forty-year range of that particular study. That would make ADRs the fourth leading 
cause of death in the US behind heart disease, cancer & strokes (Jemal, 2005). 
 
In another survey conducted by the American Society of Health-System Pharmacists, 
Johnston, et al. (2006) found that 85% of patients who responded to the survey 
expressed concerns about at least one drug-related issue, such as receiving interacting 
drugs, having harmful adverse effects from a drug, or receiving the wrong drug. ADRs 
are a significant public health problem in the world. For the 12,261,737 Medicare 
patients admitted to US hospitals, ADRs were projected to cause the following 
increases: 2976 deaths, 118,200 patient-days, $516,034,829 in total charges, 
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$37,611,868 in drug charges, and $9,456,698 in laboratory charges (Bond & Raehl, 
2006). 
 
The Institute of Medicine, (2000) reported that there were about 100,000 deaths in the 
US due to medical errors of which about 7,000 were attributed to drug reactions. Not 
only do ADRs cause death and injury but they also affect the length of stay in hospitals 
which in turns lead to increased health care costs and decreased patient’s productivity. 
Moura, et al. (2009) determined the frequency of ADRs in intensive care units and to 
evaluate their effect on the length of stay found out that each ADR presented by the 
patient was related to an increase of 2.38 days in the ICU. 
 
In research done at the University of Liverpool 18,820 patients were assessed. These 
were aged older than 16 years and were admitted to two of the national health service 
(NHS) hospitals in the region over a 6-month period. They found that a total of 1225 
admissions were related to an ADR, giving a prevalence of 6.5%. The average stay was 
8 days, which accounted for 4% of the hospital bed capacity (Nainggolan, 2004). Lesar, 
et al., (1997) evaluated drug-prescribing errors in a teaching hospital for a 9-year 
experience of prescription behavior. They showed that a total of 11,186 confirmed drug-
prescribing errors with potential for adverse patient consequences were detected and 
averted during the study period. 
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Another prospective cohort study was carried out to evaluate more than 1200 outpatient 
prescriptions, surveyed patients, and conduct a chart review during a 4-week period. 
The researchers discovered that 25% of patients experienced an ADR with selective 
serotonin-reuptake inhibitors, beta blockers, angiotensin-converting-enzyme inhibitors, 
and nonsteroidal anti-inflammatory drug classes the most frequently implicated. The 
rate of ADRs has approached 27 per 100 patients (Gandhi, et al., 2003). 
 
ADR reporting has yet to be developed adequately. The need for increased awareness of 
the importance of ADR reporting is vital in Malaysia (Aziz & Siang, 2007). It is 
documented that hospital admissions due to drug and chemical poisoning are not 
reported separately as a health performance indicator, but are collectively reported with 
other cases of accidental injury precluding its use to estimate the prevalence of 
poisoning (Rajasuriar, 2007). 
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2.3. Factors affecting the occurrence of ADRs 
2.3.1. Background  
Pirmohamed, et al., (1994) suggested that for most adverse reactions, particularly the 
idiosyncratic drug reactions, predisposition seems to be multifactorial, involving not 
only defects at multiple gene loci but also environmental factors such as concomitant 
infection or the use of other drugs for different diseases. The majority of ADRs occur as 
a result of the extension of the desired pharmacologic effects of a drug, often due to the 
substantial variability in the pharmacokinetics and pharmacodynamics seen among 
patients. For instance; drugs with a narrow therapeutic index, such as warfarin and 
digoxin, are at higher risk for causing ADRs, particularly when toxicity can occur at 
drug concentrations at or near the upper end of the therapeutic range. 
 
Pharmacological, immunological, and genetic factors are involved in the pathogenesis 
of ADRs. Factors that predispose to pharmacological ADRs include dose, drug 
formulation, pharmacokinetic or pharmacodynamic abnormalities, and drug 
interactions. The metabolic conversion of drugs to chemically reactive products is now 
established as a requirement for many idiosyncratic drug reactions (Masubuchi, et al., 
2007). Increased levels of reactive drug metabolites, their impaired detoxification, or 
decreased cellular defense against reactive drug products appears to be an important 
initiating factor (Guengerich, et al., 2007). Immunological and genetic factors may play 
a role in the reaction of the body towards the drugs given. Torpet, et al. (2004) 
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suggested ethnic variations also play an important role in the development of ADRs. 
Further details on each factor will be discussed under each sub title below. 
 
Evans (2005) found that some risk factors are consistent for all ADRs and across 
multiple therapeutic classes of drugs, while others are class specific. High-risk agents 
should be closely monitored based on patient characteristics (gender, age, weight, 
creatinine clearance, number of comorbidities) and drug administration (dosage, 
administration route, number of concomitant drugs). 
 
Factors which might increase the possibility of the occurrence of ADRs include; 
extremes of age, gender, multiple drugs, disease state, past history of ADR or allergy, 
genetic factors, large doses and many other factors as mentioned later in this chapter. 
Some studies show similarities in the incidence of ADRs between male and female 
gender even though the majority of deaths involved persons 60 years of age and older 
(Chyka, 2000). On the other hand; Martin, et al. (1998) showed that age and sex 
differences may contribute in the development of ADRs, In general practice in England 
for example, suspected ADRs to newly marketed drugs are recorded more often in 
adults aged between 30 and 59 years of age and are 60% more common in women than 
in men. The sex difference occurs in all age groups over 19 years of age. 
 
 
